Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial).
a study on Pancreatic Cancer
Pancreatic Cancer Stage IV Pancreating Cancer Cancer Stage IV gemcitabine nivolumab cabiralizumab BMS-986227 FPA008 GemCaN Stand Up to Cancer Pancreatic Neoplasms Nivolumab 10 MG/ML Intravenous Solution [OPDIVO] gemcitabine +nivolumab + cabiralizumab
Lead Scientists at UCSD
- Hitendra Patel, MD
Associate Clinical Professor, Medicine, Vc-health Sciences-schools
- Andrew Lowy, MD
Dr. Andrew M. Lowy is a surgical oncologist with a primary interest in cancers of the pancreas, liver and GI tract. He has a specialty interest in the management of patients with metastatic disease to the liver and peritoneum.
- currently not accepting new patients, but might later
- Start Date
- Completion Date
- Hitendra Patel
- Phase 2 Pancreatic Cancer Research Study
- Study Type
- Expecting 40 study participants
- Last Updated